373 related articles for article (PubMed ID: 25814078)
1. The choice of first-line chronic myelogenous leukemia treatment.
Fava C; Rege-Cambrin G; Saglio G
Ann Hematol; 2015 Apr; 94 Suppl 2(Suppl 2):S123-31. PubMed ID: 25814078
[TBL] [Abstract][Full Text] [Related]
2. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
[TBL] [Abstract][Full Text] [Related]
4. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
6. [Tyrosine kinase inhibitors for the treatment of CML].
Heim D
Ther Umsch; 2006 Apr; 63(4):249-54. PubMed ID: 16689455
[TBL] [Abstract][Full Text] [Related]
7. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
Druker BJ; Guilhot F; O'Brien SG; Gathmann I; Kantarjian H; Gattermann N; Deininger MW; Silver RT; Goldman JM; Stone RM; Cervantes F; Hochhaus A; Powell BL; Gabrilove JL; Rousselot P; Reiffers J; Cornelissen JJ; Hughes T; Agis H; Fischer T; Verhoef G; Shepherd J; Saglio G; Gratwohl A; Nielsen JL; Radich JP; Simonsson B; Taylor K; Baccarani M; So C; Letvak L; Larson RA;
N Engl J Med; 2006 Dec; 355(23):2408-17. PubMed ID: 17151364
[TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis.
Thota NK; Gundeti S; Linga VG; Coca P; Tara RP;
Indian J Cancer; 2014; 51(1):5-9. PubMed ID: 24947087
[TBL] [Abstract][Full Text] [Related]
9. Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients.
Hochhaus A; Ernst T; Eigendorff E; La Rosée P
Ann Hematol; 2015 Apr; 94 Suppl 2():S133-40. PubMed ID: 25814079
[TBL] [Abstract][Full Text] [Related]
10. A review of the European LeukemiaNet recommendations for the management of CML.
Baccarani M; Castagnetti F; Gugliotta G; Rosti G
Ann Hematol; 2015 Apr; 94 Suppl 2():S141-7. PubMed ID: 25814080
[TBL] [Abstract][Full Text] [Related]
11. Multifaceted mechanisms for cell survival and drug targeting in chronic myelogenous leukemia.
Kuroda J; Shimura Y; Yamamoto-Sugitani M; Sasaki N; Taniwaki M
Curr Cancer Drug Targets; 2013 Jan; 13(1):69-79. PubMed ID: 22414011
[TBL] [Abstract][Full Text] [Related]
12. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
[TBL] [Abstract][Full Text] [Related]
13. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
[TBL] [Abstract][Full Text] [Related]
14. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
15. Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy.
Shami PJ; Deininger M
Leukemia; 2012 Feb; 26(2):214-24. PubMed ID: 21844872
[TBL] [Abstract][Full Text] [Related]
16. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Wongboonma W; Thongnoppakhun W; Auewarakul CU
Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
[TBL] [Abstract][Full Text] [Related]
17. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
[TBL] [Abstract][Full Text] [Related]
18. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2016 Feb; 91(2):252-65. PubMed ID: 26799612
[TBL] [Abstract][Full Text] [Related]
19. [Therapeutic strategy for chronic myeloid leukemia: possibilities and prospects].
Turkina AG; Chelysheva EIu
Ter Arkh; 2013; 85(7):4-9. PubMed ID: 24137941
[TBL] [Abstract][Full Text] [Related]
20. Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.
Giles FJ; DeAngelo DJ; Baccarani M; Deininger M; Guilhot F; Hughes T; Mauro M; Radich J; Ottmann O; Cortes J
Semin Oncol; 2008 Feb; 35(1 Suppl 1):S1-17; quiz S18-20. PubMed ID: 18346528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]